Unconfirmed overall response rates from early Phase 1 readouts of ERAS-0015, a once-daily oral pan-RAS molecular glue, were 62% in second-line or later KRAS G12X NSCLC at pharmacologically active doses of 16–32 mg, 75% in post-ICI/platinum NSCLC at the same range, and 64% at the recommended dose for expansion of 24–32 mg. In second-line KRAS G12X pancreatic cancer, unconfirmed ORR was 40% at 16–32 mg, 42% at 24–32 mg, and 50% at 32 mg (N=2). Safety in dose escalation was characterized by mostly low-grade adverse events, no dose-limiting toxicities up to 40 mg, low rates of dose modification, and no discontinuations attributed to treatment. Circulating tumor DNA reductions were pronounced at active doses, with all evaluable patients showing at least 75% decline in KRAS G12X variant allele fraction. Most responders remained on treatment at data cutoff.
The core development is Erasca’s preliminary dose-escalation data from AURORAS-1 in the U.S. alongside pooled data from a parallel China study, leading to selection of 24 mg and 32 mg as expansion doses and initiation of monotherapy expansion and panitumumab combination cohorts ahead of prior guidance. Pharmacokinetics were dose-proportional with no plateau observed up to a 40 mg maximum administered dose. Early combinability signals with panitumumab in colorectal cancer (N=3) showed no DLTs and one unconfirmed partial response. The company narrowed its guidance to disclose selected monotherapy expansion and combination escalation data in the first half of 2027 and, separately, flagged preliminary Phase 1 monotherapy data for its pan-KRAS program ERAS-4001 in the second half of 2026.
Strategically, this is an attempt to plant a flag in pan-RAS territory while competitors advance mutant-selective or multi-mutant KRAS inhibitors. Cross-trial benchmarks presented by the company suggest higher early ORR versus other pan-KRAS efforts, but the signal is unconfirmed, pooled across geographies and designs, and bound to early assessment windows. The emphasis on monotherapy activity, if durable, could reduce dependence on complex combination regimens that bring cumulative toxicity and operational drag. At the same time, the panitumumab arm signals a pragmatic path for colorectal cancer, where EGFR-mediated feedback has limited monotherapy KRAS effectiveness and combinations have become table stakes.
For sites, these expansions target large, molecularly well-defined pools in NSCLC and PDAC with broad KRAS G12X eligibility, potentially easing screening logistics relative to allele-specific programs. An oral, once-daily regimen and a low DLT profile simplify clinic workflows, though widespread ctDNA monitoring will add central lab coordination and data operations overhead. For sponsors and CROs, the depth of ctDNA suppression offers an early PD anchor for go/no-go decisions, but regulatory credibility will hinge on confirmed responses, duration metrics, and consistency across G12X subtypes. Regulators will likely discount cross-study comparisons and focus on durability in PDAC and post-ICI NSCLC, where bar-raising single-arm outcomes are required to support expedited pathways.
The next phase will test whether high early ORR converts into durable, confirmable responses with manageable chronic toxicity as exposure lengthens and combinations scale. Watch for confirmation rates at 8- and 14-week landmarks rolling into DOR, PFS, and time-to-response; AE evolution with longer dosing given wildtype RAS inhibition; and the tolerability profile of EGFR combinations where dermatologic and GI events often become gating. Dose selection between 24 mg and 32 mg will need clearer differentiation, including exposure–response and AE tradeoffs. Subgroup reads across G12D, G12V, G12R, and co-mutation contexts, along with a credible randomized strategy in PDAC or post-ICI NSCLC, will determine whether this early momentum translates into a registrational path. Competitive dynamics with other pan-KRAS programs and the timing gap to the H1 2027 readout will also pressure partnering, resourcing, and trial placement decisions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
